Hyperbranched poly(amine-ester) based hydrogels for controlled multi-drug release in combination chemotherapy

Biomaterials

Volumn 31, Issue 20, 2010, Pages 5445-5454

  Zhang, Hongbin ^a   Zhao, Chen ^b   Cao, Hui ^a   Wang, Guojie ^a   Song, Li ^a   Niu, Guoguang ^a   Yang, Huai ^a   Ma, Jie ^b   Zhu, Siquan ^c  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY BEIJING   (China)

^b CANCER HOSPITAL   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Anticancer drugs; Combination therapy; Controlled release; Hydrogel; Hyperbranched poly(amine ester)

Indexed keywords

5-FLUOROURACIL; AMMONIUM PERSULFATE; ANTICANCER DRUG; AQUEOUS SOLUTIONS; BODY TEMPERATURE; COMBINATION CHEMOTHERAPY; COMBINATION THERAPY; CONTROLLED RELEASE; DOXORUBICIN HYDROCHLORIDE; DRUG DELIVERY SYSTEM; DRUG MOLECULES; DRUG RELEASE; HIGH-CONTENT; HYPERBRANCHED POLY(AMINE-ESTER); IN-VITRO; INJECTABLE HYDROGELS; INJECTABLE SYSTEMS; LOW CONCENTRATIONS; MACROMERS; MCF-7 CELLS; MODEL DRUGS; MODIFICATION DEGREES; REDOX SYSTEMS; SWELLING BEHAVIOR; TERTIARY AMINE;

AMMONIUM COMPOUNDS; BIOCOMPATIBILITY; CALCIUM; CELL CULTURE; CELL PROLIFERATION; CHEMOTHERAPY; DENDRIMERS; DRUG DELIVERY; ESTERIFICATION; ESTERS; SYNTHESIS (CHEMICAL);

HYDROGELS;

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DOXORUBICIN; FLUOROURACIL; FOLINATE CALCIUM; POLYAMINE DERIVATIVE; TERTIARY AMINE;

ANIMAL CELL; AQUEOUS SOLUTION; ARTICLE; BIOCOMPATIBILITY; BIODEGRADATION; BODY TEMPERATURE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL STRAIN L 929; CELL STRAIN MCF 7; CHEMICAL MODIFICATION; COMBINATION CHEMOTHERAPY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENCAPSULATION; HUMAN; HUMAN CELL; HYDROGEL; IN VITRO STUDY; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; POLYMERIZATION; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE; DELAYED-ACTION PREPARATIONS; DENDRIMERS; DOXORUBICIN; ESTERS; FLUOROURACIL; HUMANS; HYDROGELS; LEUCOVORIN; MAGNETIC RESONANCE SPECTROSCOPY; MATERIALS TESTING; MICE; MOLECULAR WEIGHT; TIME FACTORS;

EID: 77952583820     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.03.034     Document Type: Article

References (52)

1. Makin G., Dive C. Apoptosis and cancer chemotherapy. Trends Cell Biol 2001, 11:S22-S26.
2. Wagner A.D., Grothe W., Haerting J., Kleber G., Grothey A., Fleig W.E. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006, 24:2903-2909.
3. Presant C.A., Wolf W., Waluch V., Wiseman C.L., Weitz I., Shani J. Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: an in vivo human study using noninvasive F-19-magnetic resonance spectroscopy. J Clin Oncol 2000, 18:255-261.
4. Ravid A., Rocker D., Machlenkin A., Rotem C., Hochman A., Kessler-Icekson G., et al. 1,25-Dihydroxyvitamin D-3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res 1999, 59:862-867.
5. Solit D.B., Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov Today 2008, 13:38-43.
6. Keyomarsi K., Moran R.G. Mechanism of the cyto-toxic synergism of fluoropyrimidines and folinic acid in mouse leukemic-cells. J Biol Chem 1988, 263:14402-14409.
7. Harries M., Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol 2002, 3:529-536.
8. Reich S., Overberg-Schmidt U.S., Buhrer C., Henze G. Low-dose chemotherapy with vinblastine and methotrexate in childhood desmoid tumors. J Clin Oncol 1999, 17:1086.
9. von Minckwitz G., Costa S.D., Eiermonn W., Blohmer J.U., Tuluson A.H., Jackisch C., et al. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 1999, 17:1999-2005.
10. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006, 6:688-701.
11. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
12. Lammers T., Hennink W.E., Storm G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer 2008, 99:392-397.
13. Davis M.E., Chen Z., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
14. Huang S.L. Liposomes in ultrasonic drug and gene delivery. Adv Drug Deliv Rev 2008, 60:1167-1176.
15. Malam Y., Loizidou M., Seifalian A.M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009, 30:592-599.
16. Tamber H., Johansen P., Merkle H.P., Gander B. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv Drug Deliv Rev 2005, 57:357-376.
17. Husseini G.A., Pitt W.G. Micelles and nanoparticles for ultrasonic drug and gene delivery. Adv Drug Deliv Rev 2008, 60:1137-1152.
18. Faraji A.H., Wipf P. Nanoparticles in cellular drug delivery. Bioorg Med Chem 2009, 17:2950-2962.
19. Hamidi M., Azadi A., Rafiei P. Hydrogel nanoparticles in drug delivery. Adv Drug Deliv Rev 2008, 60:1638-1649.
20. Hoare T.R., Kohane D.S. Hydrogels in drug delivery: progress and challenges. Polymer 2008, 49:1993-2007.
21. Baumann M.D., Kang C.E., Stanwick J.C., Wang Y.F., Kim H., Lapitsky Y., et al. An injectable drug delivery platform for sustained combination therapy. J Control Release 2009, 138:205-213.
22. Ta H.T., Dass C.R., Larson I., Choong P.F.M., Dunstan D.E. A chitosan-dipotassium orthophosphate hydrogel for the delivery of Doxorubicin in the treatment of osteosarcoma. Biomaterials 2009, 30:3605-3613.
23. Jeong B., Bae Y.H., Lee D.S., Kim S.W. Biodegradable block copolymers as injectable drug-delivery systems. Nature 1997, 388:860-862.
24. Gutowska A., Jeong B., Jasionowski M. Injectable gels for tissue engineering. Anat Rec 2001, 263:342-349.
25. Van Tomme S.R., van Steenbergen M.J., De Smedt S.C., van Nostrum C.F., Hennink W.E. Self-gelling hydrogels based on oppositely charged dextran microspheres. Biomaterials 2005, 26:2129-2135.
26. Jeong B., Kim S.W., Bae Y.H. Thermosensitive sol-gel reversible hydrogels. Adv Drug Deliv Rev 2002, 54:37-51.
27. Ruel-Gariepy E., Leroux J.C. In situ-forming hydrogels - review of temperature-sensitive systems. Eur J Pharm Biopharm 2004, 58:409-426.
28. Bonacucina G., Spina M., Misici-Falzi M., Cespi M., Pucciarelli S., Angeletti M., et al. Effect of hydroxypropyl beta-cyclodextrin on the self-assembling and thermogelation properties of Poloxamer 407. Eur J Pharm Sci 2007, 32:115-122.
29. Jeon O., Bouhadir K.H., Mansour J.M., Alsberg E. Photocrosslinked alginate hydrogels with tunable biodegradation rates and mechanical properties. Biomaterials 2009, 30:2724-2734.
30. Holland T.A., Tessmar J.K.V., Tabata Y., Mikos A.G. Transforming growth factor-beta 1 release from oligo(poly(ethylene glycol) fumarate) hydrogels in conditions that model the cartilage wound healing environment. J Control Release 2004, 94:101-114.
31. Kretlow J.D., Klouda L., Mikos A.G. Injectable matrices and scaffolds for drug delivery in tissue engineering. Adv Drug Deliv Rev 2007, 59:263-273.
32. Kolhe P., Misra E., Kannan R.M., Kannan S., Lieh-Lai M. Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int J Pharm 2003, 259:143-160.
33. Zhong Z.Y., Song Y., Engbersen J.F.J., Lok M.C., Hennink W.E., Feijen J. A versatile family of degradable non-viral gene carriers based on hyperbranched poly(ester amine)s. J Control Release 2005, 109:317-329.
34. Scholl M., Kadlecova Z., Klok H.A. Dendritic and hyperbranched polyamides. Prog Polym Sci 2009, 34:24-61.
35. Gao C., Yan D. Hyperbranched polymers: from synthesis to applications. Prog Polym Sci 2004, 29:183-275.
36. Uhrich K. Hyperbranched polymers for drug delivery. Trends Polym Sci 1997, 5:388-393.
37. Bouhadir K.H., Alsberg E., Mooney D.J. Hydrogels for combination delivery of antineoplastic agents. Biomaterials 2001, 22:2625-2633.
38. Wei L., Cai C.H., Lin J.P., Chen T. Dual-drug delivery system based on hydrogel/micelle composites. Biomaterials 2009, 30:2606-2613.
39. Shin H.C., Alani A.W.G., Rao D.A., Rockich N.C., Kwon G.S. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. J Control Release 2009, 140:294-300.
40. Abraham S.A., McKenzie C., Masin D., Ng R., Harasym T.O., Mayer L.D., et al. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res 2004, 10:728-738.
41. Tardi P.G., Gallagher R.C., Johnstone S., Harasym N., Webb M., Bally M.B., et al. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta Biomembr 2007, 1768:678-687.
42. Vicent M.J., Greco F., Nicholson R.I., Paul A., Griffiths P.C., Duncan R. Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew Chem Int Ed 2005, 44:4061-4066.
43. Greco F., Vicent M.J. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev 2009, 61:1203-1213.
44. Lammers T., Subr V., Ulbrich K., Peschke P., Huber P.E., Hennink W.E., et al. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 2009, 30:3466-3475.
45. Lammers T. Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations. Adv Drug Deliv Rev 2010, 62:203-230.
46. Lu Y., Lin D., Wei H., Shi W. Synthesis and characterization of hyperbranched poly(amine-ester). Acta Polym Sin 2000, 4:411-414.
47. Fritz J.S., Schenk G.H. Acid-catalyzed acetylation of organic hydroxyl groups. Anal Chem 1959, 31:1808-1812.
48. Zhang T., Zhang Z., Dong M., Zhang J., Lin Q., Jiangw D. The influence of polyethylene imine on the gelcasting of SiC with two different initiators. J Am Ceram Soc 2007, 90:3748-3752.
49. Fang Y., Yu H., Chen L., Chen S. Facile glycerol-assisted synthesis of N-vinyl pyrrolidinone-based thermosensitive hydrogels via frontal polymerization. Chem Mater 2009, 21:4711-4718.
50. Raeber G.P., Lutolf M.P., Hubbell J.A. Molecularly engineered PEG hydrogels: a novel model system for proteolytically mediated cell migration. Biophys J 2005, 89:1374-1388.
51. Baek H.S., Yoo J.Y., Rah D.K., Han D.W., Lee D.H., Kwon O.H., et al. Evaluation of the extraction method for the cytotoxicity testing of latex gloves. Yonsei Med J 2005, 46:579-583.
52. Shim W.S., Kim J.H., Park H., Kim K., Kwon I.C., Lee D.S. Biodegradability and biocompatibility of a pH- and thermo-sensitive hydrogel formed from a sulfonamide-modified poly(ε-caprolactone-co-lactide)-poly(ethylene glycol)-poly(ε-caprolactone-co-lactide) block copolymer. Biomaterials 2006, 27:5178-5185.